Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 22,337 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTIVE Clear all
Completed Phase 2 Interventional Results available

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

NCT00129441
View directory record Official record
Conditions
Schizophrenia
Interventions
Merck L-830982, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

NCT01590654
View directory record Official record
Conditions
Hepatitis B
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Frequency of Aerobic/Resistance Training in Older Women

NCT01031394
View directory record Official record
Conditions
Aging
Interventions
Frequency of Aerobic/Resistance Training - 3 to 3
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 23, 2026, 1:29 AM EDT
Not yet recruiting Phase 4 Interventional

Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking

NCT07328594
View directory record Official record
Conditions
Smoking, Nicotine, Tobacco, Addiction, Substance Use Disorders, Insomnia, Sleep
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional Results available

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

NCT03563053
View directory record Official record
Conditions
Ataxia Telangiectasia, Genetic Syndrome
Interventions
EryDex System
Combination Product
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 23, 2026, 1:29 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

NCT03700294
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ADCT-601
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 23, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

NCT00281294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Fontolizumab
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

NCT02924766
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib, Apalutamide, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
West Hollywood, California • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

NCT07807956
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions
ABBV-253
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Completed No phase listed Observational Results available

Platelet Activity in Vascular Surgery and Cardiovascular Events

NCT02106429
View directory record Official record
Conditions
Cardiovascular Disease, Peripheral Artery Disease, Critical Limb Ischemia
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The FAITH! Trial: A mHealth Intervention to Improve Cardiovascular Health Among African-Americans

NCT03777709
View directory record Official record
Conditions
Cardiovascular Diseases, Physical Activity, Diet Modification, Lifestyle Factors
Interventions
FAITH! App
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise and Therapeutic Learning Among Women With PTSD

NCT04113798
View directory record Official record
Conditions
PTSD
Interventions
Day 1 Assessments, Day 2 Fear Learning, Day 3 Fear Extinction, Moderate Intensity Exercise, Low Intensity Exercise, Day 4 Recall of Fear Extinction
Other · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes

NCT03150199
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Positive Psychology + Motivational Interviewing, MI-based Health Education Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-based Communication for Blood Donation in Ghana

NCT05973890
View directory record Official record
Conditions
Increase Repeat Blood Donation Attempts Among First-time Donors
Interventions
WhatsApp, docudrama
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

Stimulating Language in Subacute StrokE

NCT02674490
View directory record Official record
Conditions
Stroke
Interventions
A-tDCS (1 mA), SALT, Sham
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

NCT03421197
View directory record Official record
Conditions
Psoriasis
Interventions
PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
74
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Not applicable Interventional

Aphasia Physical EXercise Study: Randomized Trial

NCT07281313
View directory record Official record
Conditions
Aphasia, Acquired, Aphasia, Aphasia, Fluent, Aphasia, Non-fluent, Aphasia Following Cerebral Infarction, Aphasia Following Nontraumatic Intracerebral Hemorrhage
Interventions
High-intensity physical exercise, Low-intensity physical exercise
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Berkeley, California • Hayward, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development and Preliminary Trial of a Brief, Portable Health Intervention for Rural Sexual Minority Emerging Adults

NCT03751020
View directory record Official record
Conditions
Depression, Suicidality, Substance Abuse, HIV, Minority Stress
Interventions
Expressive Writing (EW) Intervention, Self-Affirmation (SA) Intervention, Control
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 29 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Worcester, Massachusetts • Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

NCT06104124
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
37
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

NCT05692024
View directory record Official record
Conditions
Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis, Fibrosis, Liver, Ultrasound Elastography, Proton Magnetic Resonance Spectroscopy
Interventions
Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule., Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional

The Effect of Cognitive Behavioral Therapy for Insomnia on Type 2 Diabetes Health Outcomes

NCT03713996
View directory record Official record
Conditions
Type2 Diabetes, Insomnia
Interventions
Cognitive behavioral therapy for insomnia, Health Education
Behavioral · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Not applicable Interventional

Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)

NCT07111390
View directory record Official record
Conditions
Depression, MDD, Major Depressive Disorder, Major Depressive Episode
Interventions
60Hz Intermittent Light Therapy, Sham Light Therapy
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
24 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional Results available

Pediatric Chronic Kidney Disease Safety and Efficacy

NCT01277510
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions
cinacalcet capsule, placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 23, 2026, 1:29 AM EDT